Vitamin D-Loaded Nanostructured Lipid Carrier (NLC): A New Strategy for Enhancing Efficacy of Doxorubicin in Breast Cancer Treatment

References

• Mehta RG and Mehta RR: Vitamin D and cancer. J Nutr Biochem 13, 252–264, 2002.
   PubMed Web of Science ®Google Scholar
• Williams JD, Aggarwal A, Swami S, Krishnan AV, Ji L, et al.: Tumor autonomous effects of Vitamin D deficiency promote breast cancer metastasis. Endocrinology 157, 1341–1347, 2016.
   PubMed Web of Science ®Google Scholar
• Zeichner SB, Koru-Sengul T, Shah N, Liu Q, Markward NJ, et al.: Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin Breast Cancer 15, e1–e11, 2015.
   PubMedGoogle Scholar
• Ramalho MJ, Loureiro JA, Gomes B, Frasco MF, Coelho MA, et al.: PLGA nanoparticles as a platform for vitamin D-based cancer therapy. Beilstein J Nanotechnol 6, 1306–1318, 2015.
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, Chi K, de Wit R, Berry WR, et al.: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29, 2191–2198, 2011.
   PubMed Web of Science ®Google Scholar
• Ferguson LR, Laing B, Marlow G, and Bishop K: The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: Focus on genetic and genomic technologies. Mol Nutr Food Res 60, 119–133, 2016.
   PubMed Web of Science ®Google Scholar
• Luo Y, Teng Z, and Wang Q: Development of zein nanoparticles coated with carboxymethyl chitosan for encapsulation and controlled release of vitamin D3. J Agric Food Chem 60, 836–843, 2012.
   PubMed Web of Science ®Google Scholar
• Ramalho M, Loureiro J, Gomes B, Frasco M, Coelho M, et al. PLGA Nanoparticles for Calcitriol Delivery. IEEE 4th Portuguese Meeting on Porto, Portugal, 2015.
   Google Scholar
• Almouazen E, Bourgeois S, Jordheim LP, Fessi H, and Briançon S: Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation. Pharmaceut Res 30, 1137–1146, 2013.
   PubMed Web of Science ®Google Scholar
• Fang G, Tang B, Chao Y, Xu H, Gou J, et al.: Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: A permeability and pharmacokinetic study. Mol Pharmaceut 12, 2384–2395, 2015.
   PubMed Web of Science ®Google Scholar
• Mohamad NE, Abu N, Rahman HS, Ky H, Ho WY, et al.: Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice. RSC Adv 5, 22066–22074, 2015.
   Web of Science ®Google Scholar
• Dolatabadi JEN and Omidi Y: Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems. Trends Anal Chem 77, 100–108, 2016.
   Web of Science ®Google Scholar
• Gidwani B and Vyas A: Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharmaceut Dev Technol 21, 161–171, 2016.
   PubMed Web of Science ®Google Scholar
• Martins S: Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int J Nanomed 2, 595–607, 2007.
   PubMed Web of Science ®Google Scholar
• Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, et al.: Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharmaceut 12, 1105–1120, 2015.
   PubMed Web of Science ®Google Scholar
• Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, and Samadi N: Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep 43, 99–105, 2016.
   PubMed Web of Science ®Google Scholar
• Wang F-Z, Xing L, Tang Z-H, Lu J-J, Cui P-F, et al.: Codelivery of doxorubicin and shAkt1 by poly (ethylenimine)–glycyrrhetinic acid nanoparticles to induce autophagy-mediated liver cancer combination therapy. Mol Pharmaceut 13, 1298–1307, 2016.
   PubMed Web of Science ®Google Scholar
• Tupal A, Sabzichi M, Ramezani F, Kouhsoltani M, and Hamishehkar H: Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul 33, 372–380, 2016.
   PubMed Web of Science ®Google Scholar
• Rai G, Mishra S, Suman S, and Shukla Y: Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight. Phytomedicine 23, 233–242, 2016.
   PubMed Web of Science ®Google Scholar
• Üner M: Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die Pharmazie-Int J Pharmaceut Sci 61, 375–386, 2006.
   Google Scholar
• Castelli F, Puglia C, Sarpietro MG, Rizza L, and Bonina F: Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharmaceut 304, 231–238, 2005.
   PubMed Web of Science ®Google Scholar
• Pezeshki A, Ghanbarzadeh B, Mohammadi M, Fathollahi I, and Hamishehkar H: Encapsulation of vitamin A palmitate in nanostructured lipid carrier (NLC)-effect of surfactant concentration on the formulation properties. Adv Pharmaceut Bull 4, 563, 2014.
   PubMedGoogle Scholar
• Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto E, et al.: Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharmaceut 430, 216–227, 2012.
   PubMed Web of Science ®Google Scholar
• Armat M, Bakhshaiesh TO, Sabzichi M, Shanehbandi D, Sharifi S, et al.: The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosnian J Basic Med Sci, 16, 28–34, 2016.
   PubMed Web of Science ®Google Scholar
• Hadjittofi C, Coran AG, Mogilner JG, Pollak Y, Matter I, et al.: Dietary supplementation with vitamin D stimulates intestinal epithelial cell turnover after massive small bowel resection in rats. Pediatr Surgery Int 29, 41–50, 2013.
   PubMed Web of Science ®Google Scholar
• Sherman MH, Ruth TY, Engle DD, Ding N, Atkins AR, et al.: Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80–93, 2014.
   PubMed Web of Science ®Google Scholar
• Milczarek M, ROSIŃSKA S, Psurski M, Maciejewska M, Kutner A, et al.: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 33, 433–444, 2013.
   PubMed Web of Science ®Google Scholar
• Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, et al.: Dietary vitamin D3 and 1, 25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153, 2576–2587, 2012.
   PubMed Web of Science ®Google Scholar
• Luo W, Johnson CS, and Trump DL: Vitamin D signaling modulators in cancer therapy. Vitamins Hormones 29, 433–4722016.
   Web of Science ®Google Scholar
• Wesa KM, Segal NH, Cronin AM, Sjoberg DD, Jacobs GN, et al.: Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. Nutr Cancer 67, 424–430, 2015.
   PubMed Web of Science ®Google Scholar
• Guo L-S, Li H-X, Li C-Y, Zhang S-Y, Chen J, et al.: Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways. Die Pharmazie-Int J Pharmaceut Sci 70, 117–122, 2015.
   Google Scholar
• Gupta D, Trukova K, Popiel B, Lammersfeld C, and Vashi PG: The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer. PloS one 10, e0119690, 2015.
   PubMed Web of Science ®Google Scholar
• Li B, Baylink DJ, Walter MH, Lau K-HW, Meng X, et al.: Targeted 25-hydroxyvitamin D3 1α-hydroxylase adoptive gene therapy ameliorates DSS-induced colitis without causing hypercalcemia in mice. Mol Ther 23, 339–351, 2015.
   PubMed Web of Science ®Google Scholar
• Pourgholi F, Farhad J-N, Kafil HS, and Yousefi M: Nanoparticles: Novel vehicles in treatment of Glioblastoma. Biomed Pharmacother 77, 98–107, 2016.
   PubMed Web of Science ®Google Scholar
• Dixit N, Vaibhav K, Pandey RS, Jain UK, Katare OP, et al.: Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. Biomed Pharmacother 69, 1–10, 2015.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang J, Yang L, Jiang X, Bai Z, et al.: Nanostructured lipid carriers modified with PEGylated carboxymethylcellulose polymers for effective delivery of docetaxel. RSC Adv 5, 90386–90395, 2015.
   Web of Science ®Google Scholar
• Athawale RB, Jain DS, Singh KK, and Gude RP: Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother 68, 231–240, 2014.
   PubMed Web of Science ®Google Scholar
• Luan J, Yang X, Chu L, Xi Y, and Zhai G: PEGylated long circulating nanostructured lipid carriers for Amoitone B: Preparation, cytotoxicity and intracellular uptake. J Colloid Interface Sci 428, 49–56, 2014.
   PubMed Web of Science ®Google Scholar
• Carbone C, Campisi A, Musumeci T, Raciti G, Bonfanti R, et al.: FA-loaded lipid drug delivery systems: preparation, characterization and biological studies. Eur J Pharmaceut Sci 52, 12–20, 2014.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, and Farokhzad OC: Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Del Rev 66, 2–25, 2014.
   PubMed Web of Science ®Google Scholar
• Heurtault B, Saulnier P, Pech B, Proust J-E, Benoit J-P: Physico-chemical stability of colloidal lipid particles. Biomaterials 24, 4283–4300, 2003.
   PubMed Web of Science ®Google Scholar
• Üner M, Wissing S, Yener G, and Müller R: Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Die Pharmazie-Int J Pharmaceut Sci 59, 331–332, 2004.
   Google Scholar
• González-Pardo V, Suares A, Verstuyf A, De Clercq P, Boland R, et al.: Cell cycle arrest and apoptosis induced by 1α, 25 (OH) 2 D 3 and TX 527 in Kaposi sarcoma is VDR dependent. J Steroid Biochem Mol Biol 144, 197–200, 2014.
   PubMed Web of Science ®Google Scholar
• Piotrowska A, Wierzbicka J, Nadkarni S, Brown G, Kutner A, et al.: Antiproliferative activity of double point modified analogs of 1, 25-dihydroxyvitamin D2 against human malignant melanoma cell lines. Int J Mol Sci 17, 76, 2016.
   PubMed Web of Science ®Google Scholar
• Simboli-Campbell M, Narvaez CJ, VanWeelden K, Tenniswood M, and Welsh J: Comparative effects of 1, 25 (OH) 2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42, 31–41, 1997.
   PubMed Web of Science ®Google Scholar